


Healthcare | Mid Cap
Abbott India Ltd. demonstrates outstanding financial health, anchored by exceptional profitability and a nearly debt-free balance sheet. The company consistently generates high returns and is growing its revenue and profits at a strong pace, indicating robust market demand and operational strength. Its ability to cover short-term financial needs is also very strong. However, there are some areas of mixed performance in its operational efficiency. While it collects cash from customers very quickly, it is slower at selling its inventory and shows subpar efficiency in using its total capital to generate sales. Additionally, the company distributes a large portion of its earnings as dividends, which, while rewarding for shareholders now, represents a potential risk to dividend sustainability if profits were to decline. Overall, Abbott India is a highly profitable and financially stable company with a bright growth outlook, whose main challenges are centered on improving certain operational efficiencies.
Abbott India Ltd. demonstrates outstanding financial health, anchored by exceptional profitability and a nearly debt-free balance sheet. The company consistently generates high returns and is growing its revenue and profits at a strong pace, indicating robust market demand and operational strength. Its ability to cover short-term financial needs is also very strong. However, there are some areas of mixed performance in its operational efficiency. While it collects cash from customers very quickly, it is slower at selling its inventory and shows subpar efficiency in using its total capital to generate sales. Additionally, the company distributes a large portion of its earnings as dividends, which, while rewarding for shareholders now, represents a potential risk to dividend sustainability if profits were to decline. Overall, Abbott India is a highly profitable and financially stable company with a bright growth outlook, whose main challenges are centered on improving certain operational efficiencies.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
38.14
Industry Median
30.92
Mid Cap Median
41.06
P/E RATIO
38.14
P/B RATIO
12.40
Industry Median
3.39
Mid Cap Median
7.42
P/S RATIO
8.96
Industry Median
3.36
Mid Cap Median
6.69
Others
PEG RATIO
0.00
EV/EBITDA RATIO
27.54
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹27855 as on Aug 6, 2026.
The company is on an excellent growth trajectory across the board. It has demonstrated strong and consistent growth in its revenues, operating profits, and net income. This comprehensive growth is also reflected in the increasing value for shareholders, as seen in the robust earnings per share growth. The company is also expanding its asset base, indicating investment for future activities. This all-around positive momentum suggests strong market demand and effective corporate strategy.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 14.13 | 8.74 | 9.35 | 9.57 | 8.11 |
| Operating Profit Growth Rate | 18 | 10.85 | 20.48 | 16.66 | 11.62 |
| Earnings Per Share (EPS) Growth | 15.64 | 18.87 | 26.52 | 17.75 | 9.73 |
| Asset Growth Rate | 10 | 7.86 | 13.98 | 13.94 | 9.89 |
| Net Income Growth Rate | 15.63 | 18.77 | 26.55 | 17.74 | 9.76 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 38.14 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 42.18 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 29.08 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | Lupin Ltd | 7.84 | 20.45 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Mankind Pharma Ltd | 7.61 | 52.23 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 9 | Zydus Lifesciences Ltd | 7.60 | 22.12 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 10 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 11 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 12 | Laurus Labs Ltd | 7.10 | 111.18 | Neutral | 1778.00 | 13.71 | 890.00 |
| 13 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.04 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 14 | Ipca Laboratories Ltd | 6.33 | 38.55 | Neutral | 1979.00 | 44.64 | 1184.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral